Anti-tumour necrosis factor α therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment

被引：23

作者：

Naumann, L. ^{[1
]}

Huscher, D. ^{[2
]}

Detert, J. ^{[1
]}

Spengler, M. ^{[2
]}

Burmester, G-R ^{[1
]}

Buttgereit, F. ^{[1
]}

机构：

[1] Charite, Dept Rheumatol & Clin Immunol, D-10117 Berlin, Germany

[2] German Rheumatism Res Ctr Berlin, Berlin, Germany

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2009年 / 68卷 / 12期

关键词：

SAFETY; EFFICACY;

D O I：

10.1136/ard.2009.111807

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：1934 / 1936

页数：4

共 8 条

[1]

Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center [J].

Agarwal, SK ;

Maier, AL ;

Chibnik, LB ;

Coblyn, JS ;

Fossel, A ;

Lee, R ;

Fanikos, J ;

Fiumara, K ;

Lowry, C ;

Weinblatt, ME .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (06) :872-878

[2]

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens:: current questions and tentative answers in rheumatology [J].

Buttgereit, F ;

da Silva, JAP ;

Boers, M ;

Burmester, GR ;

Cutolo, M ;

Jacobs, J ;

Kirwan, J ;

Köhler, L ;

van Riel, P ;

Vischer, T ;

Bijlsma, JWJ .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (08) :718-722

[3]

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

[4]

Fernández-Nebro A, 2007, J RHEUMATOL, V34, P2334

[5]

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies [J].

Keystone, E. ;

Emery, P. ;

Peterfy, C. G. ;

Tak, P. P. ;

Cohen, S. ;

Genovese, M. C. ;

Dougados, M. ;

Burmester, G. R. ;

Greenwald, M. ;

Kvien, T. K. ;

Williams, S. ;

Hagerty, D. ;

Cravets, M. W. ;

Shaw, T. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (02) :216-221

[6]

Moreland LW, 2006, J RHEUMATOL, V33, P854

[7]

VALIDITY AND RELIABILITY OF THE 28-JOINT COUNT FOR THE ASSESSMENT OF RHEUMATOID-ARTHRITIS ACTIVITY [J].

SMOLEN, JS ;

BREEDVELD, FC ;

EBERL, G ;

JONES, I ;

LEEMING, M ;

WYLIE, GL ;

KIRKPATRICK, J .

ARTHRITIS AND RHEUMATISM, 1995, 38 (01) :38-43

[8]

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study [J].

Weinblatt, M. E. ;

Keystone, E. C. ;

Furst, D. E. ;

Kavanaugh, A. F. ;

Chartash, E. K. ;

Segurado, O. G. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (06) :753-759

← 1 →